Peer-reviewed veterinary case report
Limits of kidney disease tests using SDMA in cats with point-of-care
By Stone, Kristy L et al.·Published in American journal of veterinary research·2026·Cat Specialist Services, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of symmetric dimethylarginine in cats using a point-of-care analyzer and commercial laboratory assay: limitations in chronic kidney disease staging.
- Species:
- cat
Plain-English summary
A study looked at how well two different tests (VCheck and Eurolyser) measure a substance called symmetric dimethylarginine (SDMA) in cats with chronic kidney disease (CKD). SDMA levels help vets determine the stage of CKD, but the results from these tests didn't match up well with a more established test (IDEXX). While both VCheck and Eurolyser showed some agreement with the IDEXX results, they weren't reliable enough for staging CKD based on just one SDMA test. It's recommended that vets use the same analyzer for monitoring SDMA levels over time to get consistent results.
People also search for: cat kidney disease test results · SDMA testing for cats · chronic kidney disease in cats treatment
Abstract
OBJECTIVE: To evaluate the precision of a point-of-care (VCheck V200) and commercial laboratory (Eurolyser commercial laboratory) assay and assess their agreement with a reference method (IDEXX commercial laboratory) for symmetric dimethylarginine (SDMA) measurement in cats. We hypothesize that the VCheck and Eurolyser assays would demonstrate acceptable precision and agreement with the reference method. METHODS: This prospective study was conducted from May 2019 to May 2023 and utilized 39 residual feline serum samples for VCheck and Eurolyser SDMA analytical precision assessment. Sixty-one feline serum samples were assessed for the agreement of SDMA results from each analyzer with the IDEXX method. RESULTS: Acceptable within- and between-run azotemic and nonazotemic Eurolyser assay and VCheck nonazotemic between-run precision was achieved. Method comparisons (58 samples) demonstrated that Eurolyser and VCheck results were not comparable to IDEXX SDMA results. Agreement with IDEXX results was moderate and substantial for VCheck and Eurolyser, respectively, when applied to feline chronic kidney disease (CKD) International Renal Interest Society staging guidelines. CONCLUSIONS: A strong positive correlation was found between VCheck, Eurolyser, and IDEXX assays. The SDMA results were not comparable between assays. Wide dispersion of a single SDMA result prohibits its use for the International Renal Interest Society CKD staging. CLINICAL RELEVANCE: VCheck and Eurolyser use for SDMA measurement in feline CKD is supported. Establishment of method-specific/analyzer-specific reference intervals and serial SDMA monitoring using the same analyzer is recommended. International Renal Interest Society CKD staging based on a single SDMA result should be avoided.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41082907/